GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Vicarious Surgical Inc (NYSE:RBOT) » Definitions » Peter Lynch Fair Value

RBOT (Vicarious Surgical) Peter Lynch Fair Value : N/A (As of Jul. 20, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Vicarious Surgical Peter Lynch Fair Value?

Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year. Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years. If 5-Year Growth Rate is greater than 25% a year, we use 25. If 5-Year Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.


The historical rank and industry rank for Vicarious Surgical's Peter Lynch Fair Value or its related term are showing as below:



RBOT's Price-to-Peter-Lynch-Fair-Value is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 1.625
* Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.

Note: Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart.


Vicarious Surgical Peter Lynch Fair Value Historical Data

The historical data trend for Vicarious Surgical's Peter Lynch Fair Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vicarious Surgical Peter Lynch Fair Value Chart

Vicarious Surgical Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Peter Lynch Fair Value
- - - - -

Vicarious Surgical Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Peter Lynch Fair Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Vicarious Surgical's Peter Lynch Fair Value

For the Medical Devices subindustry, Vicarious Surgical's Price-to-Peter-Lynch-Fair-Value, along with its competitors' market caps and Price-to-Peter-Lynch-Fair-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vicarious Surgical's Price-to-Peter-Lynch-Fair-Value Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Vicarious Surgical's Price-to-Peter-Lynch-Fair-Value distribution charts can be found below:

* The bar in red indicates where Vicarious Surgical's Price-to-Peter-Lynch-Fair-Value falls into.


;
;

Vicarious Surgical Peter Lynch Fair Value Calculation

Vicarious Surgical's Peter Lynch Fair Value for today is calculated as

Peter Lynch Fair Value=PEG Ratio*5-Year TTM EBITDA Growth Rate***EPS without NRI (TTM)
=1* N/A *-10.747
=N/A

Vicarious Surgical's EPS without NRI for the trailing twelve months (TTM) uses the latest annual data, which was $-10.75.

* Note that for companies that do not have enough quarterly data to calculate the 5-Year TTM EBITDA Growth Rate, we use the annual data for the calculation.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Please be aware that the 5-Year TTM EBITDA Growth Rate is calculated based on TTM data over the last 5 years. For quarterly reported companies, the TTM data adds up the quarterly data reported by the company within the most recent 12 months. For companies that report semi-annually, annually, or do not have enough quarterly data, GuruFocus uses the annual data as the TTM data.

If 5-Year Earnings Growth Rate is greater than 25% a year, we use 25.

If 5-Year Earnings Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.

Please note that we use the 5-year average growth rate of EBITDA per share as the growth rate for non-bank companies, as EBITDA growth is subject to less manipulations than net earnings per share. For banks, we use the 5-year average growth rate of Book Value per share as the growth rate. The reason is that EBITDA is not applicable to Banks and Book value is a relative important measurement for Banks. In the calculation, PEG=1 because Peter Lynch thinks that the fair P/E ratio of the growth stock is equal to its earnings growth rate.


Vicarious Surgical  (NYSE:RBOT) Peter Lynch Fair Value Explanation

Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year.

Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years.

Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart. In Peter Lynch chart, a fixed P/E ratio of 15 is used to draw the Earnings Line. Therefore the value reached has a P/E ratio of 15. But in Peter Lynch Fair Value calculation, P/E equals to the growth rate of EBITDA per share over the past 5 years, which is 0 instead of 15 in this case.

Vicarious Surgical's Price to Peter Lynch Fair Value Ratio for today is calculated as

Price to Peter Lynch Fair Value=Share Price/Peter Lynch Fair Value
=10.31/N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vicarious Surgical Peter Lynch Fair Value Related Terms

Thank you for viewing the detailed overview of Vicarious Surgical's Peter Lynch Fair Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Vicarious Surgical Business Description

Traded in Other Exchanges
N/A
Address
78 Fourth Avenue, Waltham, MA, USA, 02451
Vicarious Surgical Inc designs a surgical robot that enables surgeons to perform minimally invasive surgery with 3D visualization and accurate control. Its Vicarious Surgical Robotic System is designed with a focus on abdominal access and visualization through a single port.
Executives
Adam David Sachs director, 10 percent owner, officer: President and CEO C/O VICARIOUS SURGICAL INC., 78 4TH AVENUE, WALTHAM MA 02451
Sammy Khalifa director, 10 percent owner, officer: Chief Technology Officer C/O VICARIOUS SURGICAL INC., 78 4TH AVENUE, WALTHAM MA 02451
William John Kelly officer: CFO and Treasurer C/O VICARIOUS SURGICAL INC., 78 4TH AVENUE, WALTHAM MA 02451
John Mazzola officer: Chief Operating Officer TRANSMEDICS INC, 200 MINUTEMAN ROAD, ANDOVER MA 01810
June Morris officer: CLO, General Counsel and Sec C/O VICARIOUS SURGICAL INC., 78 4TH AVENUE, WALTHAM MA 02451
Khosla Ventures Opportunity Ii, L.p. 10 percent owner 2128 SAND HILL ROAD, MENLO PARK CA 94025
Khosla Ventures Opportunity Associates Ii, Llc 10 percent owner 2128 SAND HILL ROAD, MENLO PARK CA 94025
Khosla Ventures V, L.p. 10 percent owner 2128 SAND HILL ROAD, MENLO PARK CA 94025
David D Ho director UNIT 1008, 10/F, CHAMPION TOWER, 3 GARDEN ROAD, CENTRAL K3 00000
Philip Liang director C/O VICARIOUS SURGICAL INC., 78 4TH AVENUE, WALTHAM MA 02451
Brendel Victoria Carr director C/O VICARIOUS SURGICAL, INC., 78 FOURTH AVENUE, WALTHAM MA 02451
Beverly A Huss director C/O ACCURAY INCORPORATED, 1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Shrikant Patnaik other: Principal C/O VICARIOUS SURGICAL INC., 78 4TH AVENUE, WALTHAM MA 02451
Ric Fulop director C/O DESKTOP METAL, INC., 63 THIRD AVENUE, BURLINGTON MA 01803
Barry Stuart Greene 10 percent owner C/O VICARIOUS SURGICAL INC., 78 4TH AVENUE, WALTHAM MA 02451